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The potential of amphiphilic chitosan formed by grafting octanoyl chains on the chitosan backbone for
pulmonary delivery of levoﬂoxacin has been studied. The success of polymer synthesis was conﬁrmed
using FT-IR and NMR, whilst antimicrobial activity was assessed against Pseudomonas aeruginosa. Highly
dispersible dry powders for delivery as aerosols were prepared with different amounts of chitosan and
octanoyl chitosan to study the effect of hydrophobic modiﬁcation and varying concentration of polymer
on aerosolization of drug. Powders were prepared by spray-drying from an aqueous solution containing
levoﬂoxacin and chitosan/amphiphilic octanoyl chitosan. L-leucine was also used to assess its effect on
aerosolization. Following spray-drying, the resultant powders were characterized using scanning
electron microscopy, laser diffraction, dynamic light scattering, HPLC, differential scanning calorimetry,
thermogravimetric analysis and X-ray powder diffraction. The in vitro aerosolization proﬁle was deter-
mined using a Next Generation Impactor, whilst in vitro antimicrobial assessment was performed using
MIC assay. Microparticles of chitosan have the property of mucoadhesion leading to potential increased
residence time in the pulmonary mucus, making it important to test the toxicity of these formulations.
In-vitro cytotoxicity evaluation using MTT assay was performed on A549 cell line to determine the
toxicity of formulations and hence feasibility of use. The MTT assay conﬁrmed that the polymers and
the formulations were non-cytotoxic. Hydrophobically modifying chitosan showed signiﬁcantly lower
MIC (4-fold) than the commercial chitosan against P. aeruginosa. The powders generated were of suitable
aerodynamic size for inhalation having a mass median aerodynamic diameter less than 4.5 lm for
formulations containing octanoyl chitosan. These highly dispersible powders have minimal moisture
adsorption and hence an emitted dose of more than 90% and a ﬁne particle fraction (FPF) of 52%. Powders
with non-modiﬁed chitosan showed lower dispersibility, with an emitted dose of 72% and FPF of 20%, as a
result of high moisture adsorption onto the chitosan matrix leading to cohesiveness and subsequently
decreased dispersibility.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Chronic respiratory infections are difﬁcult to eradicate leading
to high rates of morbidity and mortality and high healthcare costs
[1]. Lower respiratory tract infections (LRTIs) are responsible for
the highest number of deaths in low-income countries, placing a
considerable strain on their health economies [2]. LRTIs lead to
3.2 million deaths annually worldwide, accounting for 6.7% of theglobal disease burden, and they were the 3rd leading cause of
death in 2011 [2]. A major concern with conventional antibiotic
treatment of LRTIs is the requirement of a high dose to be delivered
for effective eradication of the organism [1]. Hence, in the past dec-
ade increasing attention has been given to developing systems for
delivery of antibiotics by means of inhalation directly to the respi-
ratory epithelium [3,4].
There are very few antibiotic formulations marketed for the
treatment of pulmonary infections, e.g. Tobramycin and Aztreo-
nam inhalation solutions for nebulization. However, much
research is being conducted into engineering inhalable antibiotic
carrying nanoscale carriers such as liposomes [5,6], polymeric
nanoparticles [7,8], solid lipid nanoparticles [9,10] and polymerpirable
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get the bioﬁlm pulmonary infections associated with cystic ﬁbrosis
(CF) or chronic obstructive pulmonary disease (COPD).
CF and COPD are characterized by the presence of a thick visco-
elastic mucus layer which has mesh with average spacing of 100–
400 nm, and is responsible for failure of many treatment modali-
ties using the pulmonary route for local and systemic delivery
[12,13]. Pseudomonas aeruginosa has been reported to be the major
causal pathogen associated with approximately 80% of CF cases
[14]. Another hindrance to antibiotic penetration is the bacterial
generated multicellular surface associated bioﬁlm composite of
exopolymeric substances (EPS), such as polysaccharide, proteins
and extracellular DNA which forms a strong, sticky network hous-
ing bacterial cells and serves as a barrier delaying penetration of
antibiotics [14,15]. Polymer/lipid nanoscale systems have been
proposed to be more effective than conventional antibiotic formu-
lations as they can penetrate the bioﬁlm due to a decrease in direct
interactions between EPS and antibiotic [12,14]. Carrier-associated
delivery of antibiotic also aids in decreasing the degradation
caused by antibiotic-inactivating enzymes, such as b-lactamase
present in the bioﬁlms secreted by P. aeruginosa [14]. However,
delivery of nanoparticle systems directly to the pulmonary region
is problematic due to their instability resulting from particle–par-
ticle interaction, and poor deposition properties within the air-
ways, resulting in loss during exhalation [16]. Tsapis et al. [17]
have described a strategy whereby nanoparticles are incorporated
into microscale structures, embracing the advantages of both
nanoscale and micrometre-scale particles, enabling efﬁcient deliv-
ery using a simple dry powder inhalation (DPI) system. Micropar-
ticles formed by aggregated nanoparticles of mass median
aerodynamic diameter (MMAD) 1–5 lm, when inhaled, deposit
efﬁciently in the peripheral lung at the site of pulmonary infection.
Exposure to the humid/moist conditions of the lungs results in lib-
eration of nanoparticles. On reaching the vicinity of the bioﬁlm col-
onies, the matrix/polymer dissolves and releases the antibiotic
leading to high localized exposure [18,12].
Drugs employed in inhalation products require a size less than
approximately 5 lm. This is usually achieved by micronization/jet
milling [19]. Powders produced by such high energy processes
exhibit strong inter-particulate attractions, leading to agglomera-
tion. Moreover, micronization does not permit precise control of
particle morphology, size distribution, particle density or surface
composition leading to variations, and produces defects and/or
amorphous regions on crystal surfaces, resulting in altered aerosol-
ization properties and posing considerable formulation challenges
[20–22]. This has led to alternative ways of controlling particle size
distribution, particle porosity, surface roughness, particle density,
etc. Spray-drying has emerged as an attractive, one-step technique
for producing powders suitable for pulmonary delivery [23]. This
method also provides potential for incorporating a wide range of
excipients into the spray-drying feedstock, including dispersibility
enhancers, such as L-leucine [4,24–26]; drug-release modiﬁers,
such as glyceryl behenate [27], hydroxypropyl cellulose [28] and
poly lactic acid poly lactides [29,30], providing a convenient means
of manipulating the properties of the end product [31].
Chitosan, a naturally occurring linear copolymer of b-(1? 4)-2-
acetamido-D-glucose and b-(1? 4)-2-amino-D-glucose processed
by partial deacetylation of chitin has been extensively investigated
for transmucosal drug delivery, for instance for pulmonary, nasal
and vaginal mucosal administration [32–34] due to its low toxicity,
biodegradation, biocompatibility, mucoadhesiveness and enhance-
ment of transcellular permeation [4,16,30]. Additionally, the poten-
tial beneﬁts of chitosan and its derivatives include the following:
immune enhancing effects [35], hypercholesterolemic effects [36],
antimicrobial properties and antitumor properties [37].
Furthermore, the highly reactive primary amino groups andPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
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ties for derivatization [38,39]. For instance, polymeric amphiphiles
formed by hydrophobic modiﬁcation of chitosan, following acyla-
tion using fatty acid chains, such as stearoyl, octanoyl and palmitoyl,
have beenwidely investigated due to the potential of forming nano-
sizedmicelles for drug and gene delivery [40]. Acylated chitosan has
also been proposed to possess anti-microbial properties against the
gram-negative bacteria P. aeruginosa and Escherichia coli, which are
commonly associated with lung infections [41].
Varied strategies have been employed to engineer particles
with improved ﬂowability and aerosolization of dry powders and
subsequently powder performance. These include modiﬁcation of
particle surface [42,43], porous low density particles [44] and
inclusion of coarser carrier particles and excipients. Current excip-
ients used for pulmonary delivery are conﬁned to classes such as
sugars viz. lactose, trehalose, and mannose and amino acids viz.
L-leucine, trileucine and phenylalanine [45,46]. These carrier/
excipients help to reduce the interparticulate forces between drug
molecules, alter density of particles, improve surface activity and
subsequently reduce the dependence of FPF on ﬂow rate and inha-
ler type hence improving aerosolization [46]. L-leucine a hydropho-
bic amino acid in particular has been shown to possess the
capability of migration to the surface of the particle droplet in
the rapid atomization phase of spray-drying hence preventing
water from being entrapped onto the surface producing pitted par-
ticles on drying, which have a reduced contact area and conse-
quently reduced cohesion.
However, previous studies have demonstrated that L-leucine
enhances the growth of bacterial associated bioﬁlms in P. aerugin-
osa models and hence limiting its use in CF and COPD making it
absolutely necessary to ﬁnd a replacement dispersibility enhancer
for dry powders [47]. None of the previous literature studies have
shown the dispersibility enhancement effects of hydrophobically
modiﬁed chitosan. In this study, we have hydrophobically modiﬁed
chitosan and investigated the effects on the aerosolization of the
ﬂuoroquinolone antibiotic levoﬂoxacin, and the antimicrobial
activity of polymer and formulations. It would be interesting to
study the effect of hydrophobic modiﬁcation of chitosan on the dis-
persibility of the dry powders as L-leucine is a model dispersibility
enhancer which is a hydrophobic amino acid. These formulations,
optimized for levoﬂoxacin content, were prepared by spray-drying,
and were investigated for their thermal, physicochemical, antimi-
crobial, aerosolization and toxicological properties in order to
explore the potential of this formulation approach to enhancing
the delivery of levoﬂoxacin as a therapeutic inhalation aerosol for
the treatment of lung infections.2. Materials and methods
2.1. Materials
LevoﬂoxacinP98.0% purity, octanoyl chloride 99% purity and L-
leucine P98.0% purity were purchased from Sigma–Aldrich Life
Sciences (Poole, UK); (1? 4) 2-amino-2-deoxy-b-D-glucose (Chi-
tooligosaccharide) 1–3 K was purchased from Kitto Life Co. Ltd
(Kyongki, Korea); Spectra/Por pre-wetted dialysis tubing with
Molecular Weight Cut off (MWCO) 1 kDa; sodium bicarbonate
99.7% purity and HPLC grade methanol, absolute ethanol, acetoni-
trile, triﬂuoroacetic acid (TFA), acetone and chloroform were pur-
chased from Fisher Scientiﬁc Ltd. (Loughborough, UK).2.2. Synthesis of water soluble N,O-octanoyl chitosan 1–3 K
N,O-octanoyl chitosan was synthesized as shown in Fig. 1.
Chitosan oligosaccharide 1–3 K (10.0 g) was dispersed in 100 mLhobically modiﬁed chitosan for enhancing the dispersion of respirable
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position magnetic stirring, RO 10 power IKA WERKE, Germany).
20 mL octanoyl chloride mixed with 80 mL methanol was added
drop-wise and allowed to react, with magnetic stirring, at 60 C
for 30 min, after which it was stirred at room temperature for 10 h.
The solution was poured into acetone and product precipitated.
This precipitate was washed with acetone at 50–60 C and ﬁltered
through a Whatmann qualitative 110 nm ﬁlter paper. The precip-
itate was then dissolved in water, and chloroform was added to
remove traces of unreacted octanoyl chloride which fractionated
into the chloroform layer. This was repeated three times to ensure
the product was free from octanoyl chloride. The product was re-
precipitated from water at room temperature by addition of ace-
tone, then dissolved in absolute ethanol to remove unreacted
chitosan, after which it was rotary evaporated using Hei-Vap (Hei-
dolph Instruments, Gmbh, UK) at 80 C under vacuum until a dry
powder was obtained. This powder was then dissolved in water
and dialysed against deionized water at room temperature for
48 h using a Spectra/Por dialysis tubing membrane with cut off
of 1 kDa. The ﬁnal product was obtained by re-precipitation from
acetone.
2.3. Characterization of N,O-octanoyl chitosan 1–3 K
2.3.1. Proton nuclear magnetic resonance (1H NMR)
High resolution 1H NMR was recorded on a Bruker AVANCE 500
spectrometer to conﬁrm the macromolecular structure of native
chitosan and octanoyl chitosan, and to ascertain the success of
derivatization. The degree of deacetylation of native chitosan was
also calculated as per the 1H NMR spectra. The spectrum was
obtained at 298 K using 16 1H scans per sample and at a resonance
frequency of 500.13 MHz for 1H. The polymer solution was
prepared at a concentration of 1% in Deuterium oxide (D2O) for
acquiring the spectrum for chitosan, and d6-dimethyl sulfoxide
(d6-DMSO) for octanoyl chitosan.
2.3.2. Fourier Transform Infrared Spectroscopy (FT-IR)
FT-IR was performed to establish the chemical structure of the
starting and synthesized polymer and hence determine the success
of derivatization. FT-IR spectra were analysed by placing the sam-
ple on a diamond crystal of an ATR polarization assembly of Spec-
trum™ 100 spectrophotometer (PerkinElmer, UK) and scanning in
the spectral region of 4000–6500 cm1.
2.3.3. X-ray powder diffraction (XRPD)
The long range order of the molecules and hence crystallinity of
chitosan, octanoyl chitosan and spray-dried microparticles was
determined at ambient temperature using wide angle X-ray dif-
fraction with a 5th generation Rigaku Miniﬂex 600 X-ray powder
diffractometer equipped with a 600 W X-ray tube, a copper anodeFig. 1. Chitosan derivatization
Please cite this article in press as: Z. Merchant et al., Engineering hydrop
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of 40 kV and current 15 mA. Polymer samples were mounted per-
pendicular to the horizontal axis and then rotated to obtain a scan-
ning range of 2–50 2 theta at a step size of 0.010/min and step
rate of 2 step/min at 25 C and hence a scanning time of
24.05 min per sample. Spray-dried microparticles were mounted
perpendicular to the horizontal axis and then rotated to obtain a
scanning range of 2–70 2 theta at a step size of 0.010/min and
step rate of 2 step/min at 25 C and hence a scanning time of
32.5 min per sample. The relative long range order (crystallinity)
v/s non-order (amorphous) was assessed by comparison of the
data obtained by XRPD of native and acylated chitosan and
spray-dried v/s physically mixed microparticles.
2.3.4. In vitro antimicrobial assessment by MIC studies
The minimum inhibitory concentrations (MICs) of water-solu-
ble chitosan, octanoyl chitosan and microparticles were deter-
mined by the broth dilution method in 96-well microplates (BD
biosciences Falcon™, UK). Three sensitive strains of P. aeruginosa
were used for the experiment namely 10663, 8620 and 599. Brieﬂy
P. aeruginosa strains were grown in iso-sensitest broth (ISB) at
37 C. Bacterial suspension was prepared in broth and diluted to
obtain an optical density (OD) of 1 at 600 nm which corresponds
to 1  108 CFU/mL of broth, after which a 200 X dilution with the
same broth was performed to obtain 5  105 CFU/mL, which was
used in the determination of MIC.
Aqueous solutions of polymers were prepared to obtain a stan-
dard concentration of 80 mg/mL chitosan. Further dilutions were
performed in broth to obtain concentrations ranging from 40 mg/
mL to 0.625 mg/mL in a ﬁnal volume of 100 lL in each well by
serial dilution. Standard aqueous solutions of the drug levoﬂoxacin
and spray-dried powders were prepared as per the drug loading for
each formulation to obtain a concentration of 64 lg/mL of levoﬂox-
acin. Further dilutions were performed in broth to obtain concen-
trations ranging from 32 to 0.006 lg/mL in a ﬁnal volume of 100 lL
in each well. To these wells, 100 lL of the P. aeruginosa strains
(5  105 CFU/mL concentration in ISB) was added and the plates
then closed and packed into a plastic bag before incubation for
12 h at 37 C. The MIC endpoints for all the tested materials were
determined by visual inspection where no turbidity corresponded
to inhibition of growth of organism.
2.3.5. In vitro cell toxicity of polymers and spray-dried microparticles
(MTT assay)
The toxicity proﬁles of samples were evaluated over 24 h in
adenocarcinomic human alveolar basal epithelial cell line, A549.
The cells (passage no. 45–49) were cultured in 96-well plates with
100 lL Roswell Park Memorial Institute (RPMI)-1640 medium sup-
plemented with 10% foetal bovine serum (FBS)/1% antibiotic/anti-
mycotic solution (complete medium) for 24 h in a humidiﬁed 5%with octanoyl chloride.
hobically modiﬁed chitosan for enhancing the dispersion of respirable
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sions in the complete medium was added to the wells to achieve
an appropriate concentration (0–5 mg/mL; n = 3), and 10%
dimethyl sulfoxide (DMSO) was used as a positive control, and
incubated for a further 24 h, followed by addition of 40 lg/mL
MTT solution (5 mg/mL in PBS, pH 7.4) to each well. After further
incubation for 2 h, the mediumwas carefully removed and any for-
mazan crystals generated were solubilized with 100 lL DMSO.
Thereafter, the optical density (OD) was measured at 570 nm
(SpectraMAX 190, Molecular Devices). The relative cell viability
(%) was then calculated using Eq. (1)):
Cell viability ð%Þ ¼ OD of treated cells
OD of untreated cells
 100 ð1Þ2.4. Preparation of formulations
2.4.1. Spray-dried powders
Formulations for spray-drying were prepared by dissolving
individual compounds weighed accurately (SD was ±0.2 mg) on a
high accuracy analytical balance in deionized water, then mixing
solutions of the drug, polymer and excipients together and spray-
drying. The composition of the formulations is shown in Table 1.
Levoﬂoxacin raw material was spray-dried to serve as a control.
The formulations were spray-dried using a lab-scale nanospray
dryer Büchi B-90 (Büchi Labortechnik AG, Switzerland) equipped
with a piezoelectrically driven droplet atomizing technology. The
inlet temperature was 120 C, with 100% aspiration, pump ﬂow
rate 20 mL/h, gas ﬂow rate 133 L/min, 5.5 lm mesh nozzle and
instrument pressure 47 mbar. Spray-dried powders were immedi-
ately transferred to a glass vial and kept in a desiccator to prevent
crystallization. Spray-dried levoﬂoxacin:octanoyl chitosan formu-
lations were also stored at room temperature at ambient humidity
to study the effect of moisture on the spray-dried powder. Each
preparation was prepared 3 times and spray-dried to indicate the
reproducibility of the preparations.
2.4.2. Physical mixtures of powders
Powder blends were prepared by physically mixing levoﬂoxacin
and the different excipients at the ratios outlined in Table 1, using
a mortar and pestle for 15 min. In vitro aerosolization studies and
XRPD were performed on these samples alongside spray-dried
powders.
2.5. Characterization of spray-dried powder
2.5.1. Spray-drying yield, % yield and drug content
The yield of the spray-dried powders was determined gravimet-
rically and calculated as a percentage of the initial weights of for-
mulation components. The levoﬂoxacin content of the powders
was measured in triplicate using high performance liquid chroma-
tography (HPLC) (Section 2.5.5), and expressed as a percentage of
nominal content using Eq. (2).
Percentage drug content
¼ Drug content of levofloxacin obtained by HPLC
Theoretical drug content of spray dried powder 100 ð2Þ
2.5.2. Particle size distribution and zeta potential measurements
The volumemedian diameter (VMD) and the particle size distri-
bution (PSD) for all the spray-dried powders and the respective
raw materials were determined using a Sympatec laser diffraction
particle sizer (Sympatec Gmbh System-Partikel-Technik,
Germany). A RODOS/L dispersing unit, equipped with a microdos-
ing device ASPIROS/L was used. A feed rate of 50 mm/s was applied
and analysis was performed at varying pressures of 4 bar and 2 barPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.doto ensure deagglomeration of powders. Six replicate readings were
performed on a single sample and results were expressed as VMD
and Span; a common dimensionless parameter used for the quan-
tiﬁcation of distribution width based on the 10th, 50th and 90th
percentile of cumulative distribution calculated using Eq. (3):
Span ¼ Dv90 Dv10=Dv50 ð3Þ
The hydrodynamic diameter and zeta potential of the disper-
sions formed following dissolution of the spray-dried powders in
deionized water were measured by dynamic light scattering
(DLS) using the Malvern ZetaSizer Nano ZS (Malvern Instruments
Inc., UK) using 0.5% (w/v) dispersion of the respective formulations
at 25 C.
2.5.3. Crystallinity, thermal properties and water content of spray-
dried powders
2.5.3.1. Differential scanning calorimetry (DSC). Thermal analysis
was performed on accurately weighed 5 mg samples using hermet-
ically sealed aluminium pans (Tzero pans), a Q series™ DSC auto-
sampler and TA DSC Q2000 (TA instruments-Waters LLC, New
Castle, DE, USA). The melting point (Tm) of samples was recorded
under a 20 mL/min dry nitrogen gas purge at a ﬂow rate of
50 mL/min. The samples were heated at a rate of 20 C/min from
20 C to 200 C. Calibration of the instrument was performed rou-
tinely using indium as the calibrant. At least three scans were per-
formed to ensure reproducibility.
2.5.3.2. Thermogravimetric analysis (TGA). Residual water content of
spray-dried powders was performed using a Pyris 6 TGA (Perkin
Elmer, Cambridgeshire, UK). 5–10 mg samples in open ceramic
pans were placed on the balance and heated from 20 C to 500 C
at a rate of 10 C/min then held for 1 min at 500 C. The moisture
content of the samples was calculated from the weight change
between 20 C and 130 C.
2.5.4. Scanning electron microscopy (SEM)
The shape and surface morphology of the spray-dried powders
was examined using scanning electron microscopy (SEM) (FEI
Quanta 200F SEM; Eindhoven, Netherlands). Samples were pre-
pared by placing a small amount of freshly prepared spray-dried
powder on to 12.5 mm aluminium specimen pin stubs covered
with double-sided adhesive black carbon tabs (Agor Scientiﬁc,
UK) then sputter-coated with gold (Qu0rum Q150R; Quorum Tech-
nologies Ltd., Sussex, UK) prior to observation under SEM.
2.5.5. High-performance liquid chromatography (HPLC) of levoﬂoxacin
Levoﬂoxacin was quantiﬁed using reversed-phase HPLC (Agi-
lent 1260 inﬁnity series; Agilent Technologies UK Ltd., Berkshire,
UK). 20 lL samples were run at room temperature with a mobile
phase comprising 0.1% TFA in HPLC grade water at pH 2.0: HPLC
grade acetonitrile (85:15) and ﬂow rate 1 mL/min using a
15 cm  4.6 mm, 5 lm Supelco C8 column (Supelco, Bellefonte,
PA, USA) with UV detection at 294 nm. Levoﬂoxacin was quantiﬁed
by peak area measurements at a retention time of 6.25 min. A stan-
dard curve for levoﬂoxacin was constructed before each sample
analysis in triplicates. The standard curve was linear from 0.25 to
16 lg/mL, and was used to derive the standard equation for calcu-
lation of concentration of levoﬂoxacin in experimental samples.
The limit of detection and limit of quantiﬁcation of levoﬂoxacin
were calculated as per the International Conference on Harmoniza-
tion guidelines using formulae [48]:
LOD ¼ 3:3 SD=s
LOQ ¼ 10 SD=s ð4Þ
where SD is the standard deviation of the Y-intercept and s = slope
of calibration curve.hobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
Table 1
Composition of formulations investigated.
Spray-dried powders Levoﬂoxacin
(mg)
N,O-octanoyl chitosan (1–
3 K) (mg)
Chitosan (1–3 K)
(mg)
L-Leucine
(mg)
Final volume of
feedstock (mL)
Levoﬂoxacin 400 – – – 100
Levoﬂoxacin:octanoyl chitosan (4:1) 400 100 – – 125
Levoﬂoxacin:octanoyl chitosan (2:1) 400 200 – 150
Levoﬂoxacin:octanoyl chitosan (1:1) 400 400 – – 200
Levoﬂoxacin:chitosan (4:1) 400 – 100 – 125
Levoﬂoxacin:chitosan (2:1) 400 – 200 – 150
Levoﬂoxacin:chitosan (1:1) 400 – 400 – 200
Levoﬂoxacin:L-leucine (4:1) 400 – – 100 110
Levoﬂoxacin:octanoyl chitosan:L-leucine (4:0.1:0.25) 400 100 – 25 127.5
Final concentration of individual compounds mixed for
spray-drying
4 mg/mL 4 mg/mL 4 mg/mL 10 mg/mL
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The aerosolization properties of the spray-dried formulations
and physically mixed formulations were investigated using an
NGI (Copley Scientiﬁc Ltd., Nottingham, UK). Powder aliquots
(10 mg) were loaded manually into size 3 HPMC capsules and
placed into a Cyclohaler (Pharmachemie, UK) that was attached
to the NGI via a stainless steel USP throat. The capsule was pierced
and the liberated powder drawn through the NGI at a ﬂow rate of
60 L/min for 6 s, using a low capacity pump (Model LCP5; Copley
Scientiﬁc Ltd., Nottingham, UK). Stages 1–7 of the NGI were coated
with 1% silicon oil (Sigma–Aldrich, UK) in N-hexane (Fisher scien-
tiﬁc, Loughborough, UK) to prevent particle re-entrainment. A
75 mm terminal micro-oriﬁce ﬁlter was placed on Stage 8. Under
these conditions, the effective cut-off diameters are as follows:
Stage 1-8.06 lm; Stage 2-4.46 lm; Stage 3-2.26 lm; Stage
4-1.66 lm, Stage 5-0.94 lm; Stage 6-0.55 lm; Stage 7-0.34 lm,
with Stage 8 having a terminal ﬁlter (Copley Scientiﬁc, UK). After
aerosolization, each stage was rinsed with 10 mL of ultrapure
water (HPLC grade) and the drug content was quantiﬁed by
reversed-phase HPLC after diluting each stage to achieve appropri-
ate concentration as per the linearity of the calibration curve. Each
experiment was performed in triplicate. The particle size distribu-
tion of the spray-dried and physically mixed powders was
compared, determining ﬁne particle fraction (FPF) as the amount
of drug deposited on Stages 2–8 as a percentage of the total drug
collected representative of the fraction of aerosolized particles
having cut-off diameter lower than 5 lm. Mass median aerody-
namic diameter (MMAD) and geometric standard deviation (GSD)
were also calculated from the plot of log cumulative mass percent
deposited on each stage of the NGI versus the cut-off diameter of
that stage.2.7. Statistical analysis
The values obtained from different experiments were statisti-
cally compared to control spray-dried powders by using One-way
Analysis of Variance (ANOVA) and Tukey’s post hoc test. A p value
of less than 0.05 was considered signiﬁcant for all experiments. A
signiﬁcance level of p less than 0.02 has also been considered for
a few experiments to show the high signiﬁcance of the outcome
of results.3. Results and discussion
3.1. N,O-octanoyl chitosan 1–3 K characteristics
3.1.1. Synthesized polymer yields
The yield of N,O-octanoyl chitosan obtained after synthesis as
analysed by gravimetry and expressed as a percentage was 72.5%.Please cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.do3.1.2. FT-IR analysis
The FT-IR spectra for chitosan 1–3 K and N,O-octanoyl chitosan
1–3 K are shown in Fig. 2. The spectrum for Chitosan 1–3 K has
characteristic absorption peaks at ca 1636 cm1 attributed to car-
bonyl stretching of secondary amine (amide I band), at
1594.4 cm1 indicative of the NAH bending vibrations of non-acyl-
ated 2-aminoglucose primary amine and 1540.4 cm1 indicative of
the NAH bending vibration of secondary amine (amide II band) i.e.
2-acetamidoglucose. The presence of both 2-aminoglucose and 2-
acetamidoglucose units was conﬁrmed by the presence of bands
at 1636, 1594.4 and 1540.4 cm1.
On acylation of chitosan to form N,O-octanoyl chitosan, the
vibrational band attributed to the free amino group of chitosan
shifted to lower frequency and higher intensity at 1511 cm1,
attributed to the formation of N-octanoyl and hence intermolecu-
lar hydrogen bonding between the carbonyl of the octanoyl group
and the hydrophilic groups on the polymer backbone. C@O absorp-
tion by the octanoyl group is more deﬁned and prominent, with
increased intensity of the band at 1611 cm1, compared to the
band at 1636 cm1 for non-modiﬁed chitosan. The increase in
intensity and prominence of vibrational bands at 2885 cm1 of
octanoyl chitosan is attributed to absorption by the ACH2 chain
of octanoyl substituted at the primary amine of 2-aminoglucose.
Furthermore, a relatively weak vibrational band was observed at
1748 cm1 indicative of O-acylation. FT-IR conﬁrmed octanoyla-
tion of chitosan with more prominence of N-octanoylation as com-
pared to weak O-octanoylation and hence formation of N,O-
octanoyl chitosan.3.1.3. 1H NMR (proton nuclear magnetic resonance)
The 1H NMR spectra of chitosan in D2O and N,O-octanoyl chito-
san in d6-DMSO are shown in Figs. 3 and 4 respectively. The chem-
ical shift at 1.9–2.1 ppm represents three protons (ANHACOACH3)
of N-acetyl glucosamine (GlcNAc). The chemical shifts of the non-
anomeric protons connected to the ring skeleton of glucosyl resi-
due having similar electron densities show a partially overlapping
behaviour to produce a broad signal around 3.5–4.0 ppm. The
ACHAOH, HOHCACHACH2 and ACH2AOH protons appear at
around 3.75 ppm, whereas the chemical shifts of ACHACH2 and
CH2AOH appear at 3.59 ppm in both spectra. The anomeric protons
of the chitosan backbone, due to their neighbouring glycosidic and
ring oxygen, appear at higher chemical shifts compared to non-
anomeric protons, i.e. around 2.8–3.2 ppm. The degree of deacety-
lation of commercial chitosan calculated from the 1H NMR spectra
was found to be 86.42%.
Other than the native chitosan chemical shifts, the spectra of
N,O-octanoyl chitosan have three peaks at chemical shifts 0.85,
1.25 and 1.8 ppm which conﬁrms the success of acylation. The
chemical shift seen at 0.85 ppm in the 1H NMR spectrum of N,O-
octanoyl chitosan (Fig.4) can be assigned to methyl protons ACH2-
ACH3 of the octanoyl group. This peak becomes more prominenthobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
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Fig. 2. FT-IR spectra of chitosan and N,O-octanoyl chitosan. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
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Fig. 3. NMR spectrum of chitosan 1–3 K. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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intensity of the peak can be attributed to low substitution of the
octanoyl groups onto the chitosan backbone. The chemical shift
at 1.25 ppm can be attributed to the ACH2ACH3, and that appear-
ing at 1.8 ppm to ACOACH2ACH3 of the octanoyl groups. The peak
at 1.8 ppm was seen to overlap with the peak of three methyl pro-
tons (ANHACOACH3) of N-acetyl glucosamine and gives a triplet.3.1.4. XRPD (X-ray powder diffraction)
XRPD was performed to characterize the crystallographic struc-
ture of the polymers, rawmaterials, spray-dried microparticles and
physically mixed powders. The XRPD diffractogram of chitosan
(Fig. 5) shows a broad diffusive halo at around 21 indicative of
the amorphous nature of chitosan. The XRPD diffractogram of syn-
thesized N,O-octanoyl chitosan (Fig. 5) shows a similar halo around
the same 2H, however, the ‘‘hump’’ was seen to be split into twoPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.dopeaks as encountered earlier in the literature, conﬁrming the iden-
tity of successful derivatization [49]. It is assumed that the attach-
ment of an octanoyl group onto the chitosan backbone leads to the
formation of sharper peaks with generation of new peaks at 19.6
and 25.71 which forms a more stable organization and hence
enhances the stability of the polymer. XRPD analysis of spray-dried
levoﬂoxacin (Fig. 6) showed sharp diffraction peaks at 2H of 6.91,
10.0, 13.6, 16.35, 20.08 and 26.93 characteristic of high degree of
crystallinity of the drug. The diffraction pattern was similar to that
produced by unprocessed raw material (Fig. 7). Spray-dried pow-
ders containing chitosan and octanoyl chitosan showed the pres-
ence of broad diffuse peaks indicative of the long range disorder
and hence amorphous nature of the formulations (Fig. 6). However,
formulations spray-dried without chitosan (levoﬂoxacin:L-leucine
(4:1)) showed narrow diffraction peaks indicative of crystalline
nature of the powders. Physical mixtures at the same molar mass
as the spray-dried formulations (Fig. 7) showed narrow diffraction
peaks, indicating that spray-drying in the presence of chitosan or
hydrophobically-modiﬁed chitosan, leads to transformation of
the powders into an amorphous state.
3.1.5. In vitro antimicrobial activity of polymers and spray-dried
microparticles
MIC data for chitosan and synthesized N,O-octanoyl chitosan
against three planktonic strains of P. aeruginosa namely 10663,
8620 and 599 are shown in Table 2. N,O-octanoyl chitosan showed
a 4-fold decrease in MIC compared to non-modiﬁed chitosan,
hence, showing higher anti-pseudomonal activity due to its
increased hydrophobic character. Optimized levoﬂoxacin spray-
dried powders also possessed an in vitro antibacterial activity
(Table 2). Similar or a 1-fold less MIC was seen for the spray-dried
powders with octanoyl chitosan, wherein, the slight decrease in
MIC could be attributed to an additive anti-pseudomonal activity
of octanoyl chitosan as shown in Table 2.
3.1.6. In vitro cytotoxicity of the polymers and spray-dried
microparticles
The MTT assay is a reliable method to test the cytotoxicity of
polymers. Hence, A549 lung epithelial cell viability was investi-
gated by exposure to various concentrations of polymers withinhobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
Fig. 4. NMR spectrum of N,O-octanoyl chitosan 1–3 K. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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Fig. 5. X-ray diffractograms of chitosan 1–3 K and N,O-octanoyl chitosan 1–3 K.
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chitosan, by derivatization did not signiﬁcantly change (p < 0.05)
cytotoxicity to control non-modiﬁed chitosan. A cell viability ofPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.do86.71 ± 13.20% and 83.39 ± 11.24% was seen for chitosan and
N,O-octanoyl chitosan respectively at a concentration of 2.5 mg/
mL, as compared to the positive control 10% DMSO which showed
viability of only 7%. Hence, it can be deduced that the synthesized
polymer was non-toxic and would be predicted to not cause harm
to the lung epithelia under the conditions and timescale of this
study. The spray-dried formulations, i.e. spray-dried levoﬂoxa-
cin:octanoyl chitosan:L-leucine (4:1:0.25) cell viability of 88.52%,
spray-dried levoﬂoxacin:octanoyl chitosan (4:1) cell viability of
91.7%, spray-dried levoﬂoxacin:octanoyl chitosan (2:1) cell viabil-
ity of 93.74% (not shown) and spray-dried levoﬂoxacin:octanoyl
chitosan (1:1) cell viability of 85.93% (not shown) indicate that
up to concentrations of 0.3125 mg/mL formulations were well tol-
erated and not signiﬁcantly different from that of spray-dried lev-
oﬂoxacin with a cell viability 89.66% at a concentration of
0.3125 mg/mL (p < 0.05; Fig. 9). However, the viability decreased
at 1.25 mg/mL concentrations but still showed survival greater
than 50%. Consequently, it may be concluded that the spray-dried
formulations, with potential for use as dry powders inhalations to
treat pulmonary infections were non-toxic under the conditions
and timescale of study.
3.2. Spray-dried powder characteristics
3.2.1. Drug content, % yield, size and size distribution
With the innovative electrostatic collector of the Büchi B-90
nanospray dryer, yields in the range 51–79% of theoretical were
produced, dependent on composition (Table 3), with formulations
containing chitosan and hydrophobically-modiﬁed chitosan giving
statistically greater yields (p < 0.02) than spray-dried levoﬂoxacin
alone, indicating better deposition of formulations containing
chitosan in the electrostatic collector of the spray dryer. The limit
of detection and quantiﬁcation for levoﬂoxacin using HPLC-UV was
found to be 0.08 mcg and 0.25 mcg respectively. The levoﬂoxacin
content of spray-dried powders, determined by HPLC, ranged from
77% to 118% of predicted amount (Table 3). Data for size distribu-
tions of the spray-dried powders, which were unimodal, are shown
in Table 3. The VMD for all the spray-dried powders was between
2.5 and 4.6 lm, i.e. of a size appropriate for ensuring greatesthobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
Fig. 7. X-ray diffractograms of levoﬂoxacin raw material and physically mixed formulations. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
Table 2
Minimum inhibitory concentration against P. aeruginosa (P.A.) (n = 3).
Polymer Minimum inhibitory concentration
P.A. 10663 P.A. 8620 P.A. 599
Chitosan 1–3 K 20 mg/mL 40 mg/mL 20 mg/mL
N,O-octanoyl chitosan 1–3 K 5 mg/mL 10 mg/mL 5 mg/mL
Raw material levoﬂoxacin 0.25 lg/mL 0.25 lg/mL 0.5 lg/mL
Spray-dried levoﬂoxacin 0.25 lg/mL 0.25 lg/mL 0.5 lg/mL
Spray-dried levoﬂoxacin:octanoyl chitosan (4:1) 0.25 lg/mL 0.125 lg/mL 0.5 lg/mL
Spray-dried levoﬂoxacin:octanoyl chitosan (2:1) 0.125 lg/mL 0.125 lg/mL 0.5 lg/mL
Spray-dried levoﬂoxacin:octanoyl chitosan (1:1) 0.125 lg/mL 0.125 lg/mL 0.5 lg/mL
Spray-dried levoﬂoxacin:octanoyl chitosan:L-leucine (4:1:0.25) 0.125 lg/mL 0.125 lg/mL 0.5 lg/mL
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Fig. 8. MTT assay-cell viability data of chitosan 1–3 K and N,O-octanoyl chitosan 1–3 K (n = 3 ± SD). (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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ders in deionized water the size was found to be in the nanometric
range as analysed by the DLS with a small net positive charge
indicative of their formation of nanometric dispersion on exposure
to the moist surrounding of the airway epithelium where they will
be deposited.
3.2.2. Scanning electron microscopy (SEM)
SEMmicrographs of the spray-dried powders and raw materials
are shown in Fig. 10. Levoﬂoxacin (Fig. 10A) comprised irregular,
columnar, crystals having a wide size distribution. The columnar
elongated shape presents a relatively large contact area between
particles, likely to lead to cohesiveness and poor dispersibility.
Spray-dried levoﬂoxacin (Fig. 10B) comprised spherical particles
with a relatively smooth surface and size in good agreement with
that measured by laser diffraction (Table 3). Spherical particles
have decreased contact area leading to decreased cohesivenessPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.doand better dispersibility and aerosolization [50,51]. SEM micro-
graphs of spray-dried powders of levoﬂoxacin:octanoyl chitosan
(Fig. 10C–E) and levoﬂoxacin:chitosan (Fig. 10F, G and H) revealed
spherical particles, but with a less smooth, corrugated surface mor-
phology and diameters in good agreement with that measured by
laser diffraction (Table 3). Corrugations on the surface may further
decrease the contact area between particles, reducing cohesiveness
and increasing dispersibility [52]. SEM micrographs of the spray-
dried levoﬂoxacin:L-leucine formulation (Fig. 10I) which contains
about 20%w/w L-leucine, showed fractured, hollow-surfaced
spheres, with curved plates of nanometric thickness which have
been reported earlier by various authors. These have spaces which
produce an open powder which may increase dispersibility of
cohesive material by increasing median geometric diameter and
subsequently decreasing particle density [51,53,54]. The levoﬂoxa-
cin:octanoyl chitosan:L-leucine (Fig. 10J) particles contain only 5%
w/w L-leucine, and hollow surfaced curved plates are not evident.hobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
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Table 3
Physical characteristics of spray-dried powders (mean ± SD; n = 3).
Sample Yield (%) Drug content
(%)
Size–DLS
(nm)
‰-potential
DLS (mv)
VMD (lm) Span TGA mass loss
(%)
4 bar 2 bar 4 bar 2 bar
Levoﬂoxacin raw material – – – – 8.80 ± 2.06 9.63 ± 2.37 2.33 2.66 2.34 ± 0.750
Chitosan – – – – 32.29 ± 3.96 38.06 ± 4.53 1.94 1.65 6.50 ± 2.440
Octanoyl chitosan – – – – 28.57 ± 3.09 37.78 ± 3.10 2.06 1.64 15.75 ± 3.675
Spray-dried – levoﬂoxacin 51.03 ± 5.68 93.04 ± 0.27 – – 2.89 ± 0.36 3.23 ± 0.87 1.63 2.05 1.74 ± 0.880
Spray-dried – levoﬂoxacin:octanoyl
chitosan (4:1)
76.52** ± 1.26 79.13 ± 0.14 137.26 ± 1.34 +2.58 ± 0.08 2.66 ± 0.68 2.83 ± 0.69 1.62 2.72 6.94 ± 0.800
Spray-dried – levoﬂoxacin:octanoyl
chitosan (2:1)
71.33** ± 1.59 78.71 ± 0.16 183.7 ± 1.59 +1.70 ± 0.11 2.50 ± 0.41 2.61 ± 0.55 1.67 2.01 10.82 ± 0.74
Spray-dried – levoﬂoxacin:octanoyl
chitosan (1:1)
75.73** ± 2.02 85.22 ± 3.88 178.8 ± 1.86 +1.65 ± 0.41 2.53 ± 0.69 2.70 ± 0.73 1.99 2.25 11.37 ± 0.75
Spray-dried – levoﬂoxacin:chitosan
(4:1)
65.44** ± 5.09 83.69 ± 0.79 472.5 ± 2.52 +3.69 ± 0.21 3.03 ± 1.57 3.23 ± 1.61 2.78 2.62 23.99* ± 1.96
Spray-dried – levoﬂoxacin:chitosan
(2:1)
65.92** ± 5.74 77.13 ± 0.38 487.5 ± 3.06 +4.01 ± 0.55 4.21 ± 1.40 4.54 ± 1.55 3.26 1.54 21.45* ± 1.64
Spray-dried – levoﬂoxacin:chitosan
(1:1)
67.40** ± 4.96 83.76 ± 1.4 489.6 ± 2.58 +3.98 ± 0.36 3.51 ± 1.18 3.67 ± 1.26 4.26 5.61 35.05* ± 1.79
Spray-dried – levoﬂoxacin:L-leucine
(4:1)
79.06** ± 6.68 118.60 ± 4.25 315.0 ± 1.36 11.36 ± 0.61 4.13 ± 0.25 4.56 ± 0.39 3.21 3.65 2.24 ± 0.41
Spray-dried – levoﬂoxacin:octanoyl
chitosan:L-leucine (4:1:0.25)
72.88** ± 2.29 81.15 ± 4.88 367.2 ± 1.39 +1.70 ± 0.19 3.75 ± 0.59 3.87 ± 0.74 3.11 3.25 12.52 ± 0.49
* Statistical difference: One-way ANOVA/Tukey versus spray-dried levoﬂoxacin powder: p < 0.05.
** Statistical difference: One-way ANOVA/Tukey versus spray-dried levoﬂoxacin powder: p < 0.02.
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size in good agreement with that measured by laser diffraction
(Table 3). Fig. 10K shows the effect of moisture on the morphology
of the spray-dried powders containing octanoyl chitosan alone.
Spray-drying often produces amorphous particles, which in a
humid environment may sorb water and recrystallize. After
60 days storage at room temperature and ambient humidity there
was no considerable change in morphology or evidence of a change
in crystallinity of the powder, as has previously been reported for
spray-dried powders of terbutaline sulphate [4]. This suggests that
octanoyl chitosan formulations have reasonable physical stability
in ambient conditions.
3.2.3. Amorphous nature of spray-dried powders
3.2.3.1. Differential scanning calorimetry (DSC). The thermograms of
levoﬂoxacin and spray-dried powders containing octanoyl chitosanPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.doare shown in Fig. 11. The thermogram of levoﬂoxacin showed a
sharp endothermic peak with an onset at 120 C, indicative of melt-
ing and hence demonstrating the crystalline nature of rawmaterial,
in agreementwithXRPDdata (Fig. 7). TheDSC thermogramof spray-
dried powders containing octanoyl chitosandidnot showcharacter-
istic endotherms, indicating production of an amorphous form dur-
ing spray-drying. The production of an amorphous form may result
in powders having a higher solubility and faster dissolution rates in
lung ﬂuids. Furthermore, exothermic transitions around 80–95 C
were observed for the spray-dried powders which were not seen
in the thermograms of the raw materials. This corresponds to the
heat produced by the sample on phase transition indicative of
recrystallization of spray-dried powders.
3.2.3.2. Thermogravimetric analysis (TGA). Mass loss as a function of
temperature between 20 and 130 C (Table 3) is indicative of thehobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
Fig. 10. SEM micrographs of (A) Levoﬂoxacin raw material, (B) Spray-dried levoﬂoxacin, (C) Spray-dried levoﬂoxacin:octanoyl chitosan (4:1), (D) Spray-dried
levoﬂoxacin:octanoyl chitosan (2:1), (E) Spray-dried levoﬂoxacin:octanoyl chitosan (1:1), (F) Spray-dried levoﬂoxacin:chitosan (4:1), (G) Spray-dried levoﬂoxacin:chitosan
(2:1), (H) Spray-dried levoﬂoxacin:chitosan (1:1), (I) Spray-dried levoﬂoxacin:L-leucine (4:1), (J) Spray-dried levoﬂoxacin:octanoyl chitosan:L-leucine (4:1:0.25), (K) Spray-
dried levoﬂoxacin:octanoyl chitosan (4:1) on storage at room temperature and humidity. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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tistically (p < 0.05) greater weight loss for spray-dried powders
containing chitosan than for those containing hydrophobically-
modiﬁed octanoyl chitosan and L-leucine. This weight loss can be
attributed to greater adsorption of water in the matrix of the
hydrophilic chitosan polymer chains, preventing its loss during
spray-drying and resulting in higher ﬁnal water content. Spray-
dried octanoyl chitosan-containing powders showed similar
(p > 0.05) water loss as spray-dried levoﬂoxacin powder, indicating
minimal entrapment of water. Addition of octanoyl groups onto
the chitosan backbone prevents hydrophilic moisture entrapmentPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.dowithin the matrix leading to a drier ﬁnal product. This may also
result in a less cohesive powder with better ﬂow properties and
subsequently improved aerodynamic properties and FPF compared
to spray-dried formulations with chitosan.
3.2.4. In-vitro aerosol properties
The in vitro aerodynamic behaviour of powder formulations
delivered from a Cyclohaler into the NGI is shown in Figs. 12–14,
and the derived aerodynamic parameters are presented in Table 4.
All powders were highly dispersible, with at least 71.62% of the
capsule contents being emitted during aerosolization, and giving ahobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
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Fig. 11. DSC thermograms of spray-dried powders; (A) Levoﬂoxacin raw material, (B) Octanoyl chitosan, (C) Spray-dried levoﬂoxacin:octanoyl chitosan 4:1, (D) Spray-dried
levoﬂoxacin:octanoyl chitosan 2:1, (E) Spray-dried levoﬂoxacin:octanoyl chitosan:L-leucine 4:1:0.25. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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Table 4
Aerodynamic parameters for formulations delivered to the NGI.
Formulation Fraction recovered-FR
(%)
Emitted dose-ED
(%)
Fine particle fraction-FPF
(%)
MMAD
(lm)
GSD
Levoﬂoxacin 75.68 96.25* ± 5.70 8.21 ± 1.25 5.76 ± 0.108 1.89
Spray-dried levoﬂoxacin 76.93 91.59 ± 3.59 29.65 ± 2.56 4.12 ± 0.13 1.91
Spray-dried levoﬂoxacin:octanoyl chitosan (4:1) 82.67 95.62 ± 3.28 52.24* ± 1.89 4.81 ± 0.095 1.33
Spray-dried levoﬂoxacin:octanoyl chitosan (2:1) 78.45 92.66 ± 2.21 49.65* ± 2.12 4.49 ± 0.11 1.46
Spray-dried levoﬂoxacin:octanoyl chitosan (1:1) 92.63 89.89 ± 3.26 43.76* ± 1.74 4.19 ± 0.23 1.76
Spray-dried levoﬂoxacin:chitosan (4:1) 75.71 71.62*± 7.44 19.97 ± 4.601 4.16 ± 1.23 1.67
Spray-dried levoﬂoxacin:L-leucine (4:1) 83.83 92.53 ± 6.74 31.08 ± 4.68 4.79 ± 0.64 1.94
Spray-dried levoﬂoxacin:octanoyl chitosan:L-leucine (4:1:0.25) 120.24* 89.47 ± 2.66 55.33* ± 2.15 3.84 ± 0.10 2.08
Physical mixture levoﬂoxacin:octanoyl chitosan (4:1) 85.17 113.39 ± 2.66 9.77 ± 3.68 – –
Physical mixture levoﬂoxacin:octanoyl chitosan:L-leucine
(4:1:0.25)
76.04 107.85 ± 3.96 8.14 ± 3.95 – –
* Statistical difference: One-way ANOVA/Tukey versus spray-dried levoﬂoxacin powder: p < 0.05 for statistically higher values.
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macopoeial limits of 75–125%. For spray-dried levoﬂoxacin, a high
proportion of drug is deposited in the inhaler and throat region of
the NGI (Figs. 12 and 13). Spray-dried powders containing octanoyl
chitosan produced the low deposition of levoﬂoxacin in the inhaler
and throat regions, with increased deposition particularly in Stages
2 and 4 of the NGI, demonstrating the increased dispersibility of
this formulation. The powders generated were of suitable aerody-
namic size for inhalation having a mass median aerodynamic
diameter (MMAD) less than 5 lm, with formulations containing
octanoyl chitosan having MMADs less than 4.5 lm.
Spray-drying levoﬂoxacin in the presence of octanoyl chitosan
at different ratios increased the FPF by approximately 76%
compared to spray-dried drug alone. Comparing the FPF of
formulations incorporating the commonly used dispersibility
enhancer L-leucine (Fig. 14; Table 4), the FPF achieved with poly-
mer octanoyl chitosan:L-leucine was signiﬁcantly (p < 0.05) higher
than for a comparable spray-dried levoﬂoxacin:L-leucine formula-
tion. In addition, the FPF of spray-dried powders containing chito-
san was signiﬁcantly (p < 0.05) lower than spray-dried powders
containing octanoyl chitosan (Table 4). This can be attributed to
the higher moisture entrapment in the matrix of chitosan during
spray-drying, leading to cohesiveness and hence a decrease in
FPF of the spray-dried powders. Moreover, the amphiphilic nature
of octanoyl chitosan means that during spray-drying it is likely to
migrate to the solution droplet/drying air interface, resulting inPlease cite this article in press as: Z. Merchant et al., Engineering hydrop
microparticles of levoﬂoxacin, Eur. J. Pharm. Biopharm. (2014), http://dx.domodiﬁcation of the surface properties and cohesive properties of
the powders.
Previous research has demonstrated that a high content of dis-
persibility enhancers and carriers is required to increase effectively
the aerodynamics of drugs delivered as powder aerosols [4,55,56].
The present study shows that increasing polymer concentration
beyond 20% did not give any signiﬁcant improvement in dispersi-
bility, and hence formulations containing 20% octanoyl chitosan
would be favourable for use, incorporating the maximum amount
of antibiotic for delivery of a high localized dose of levoﬂoxacin.
The dispersibility of the formulations with octanoyl chitosan was
comparable with those containing L-leucine, an established disper-
sibility enhancer for aerosol formulation, showing that the deriva-
tized natural polymer, octanoyl chitosan, was a highly efﬁcient
dispersibility enhancer and hence is attractive for pulmonary
delivery of other drugs.
Powders comprising spray-dried levoﬂoxacin:octanoyl chitosan
and levoﬂoxacin:octanoyl chitosan:L-leucine were compared with
physical mixtures of the same composition. Both the physical mix-
tures showed deposition behaviour within the NGI comparable
with levoﬂoxacin raw material, with deposition high in the impac-
tor. These formulations produced FPFs similar to raw material and
signiﬁcantly lower FPFs (p < 0.05) than their spray-dried counter-
parts (Table 4). Thus, simple mixing of levoﬂoxacin with octanoyl
chitosan or L-leucine did not improve the deposition proﬁle of lev-
oﬂoxacin. Consequently, formulating levoﬂoxacin within a deliveryhobically modiﬁed chitosan for enhancing the dispersion of respirable
i.org/10.1016/j.ejpb.2014.09.005
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ponents are included in individual, spherical particles is required.
4. Conclusion
The present investigation has shown that derivatization of
chitosan with a hydrophobic octanoyl chain increased the
in vitro antimicrobial activity of the polymer. Moreover, spray-
dried microparticles containing octanoyl chitosan showed a
greater dispersibility and higher FPF when compared to those con-
taining non-modiﬁed chitosan, demonstrating its suitability as an
alternative inhalation aerosol dispersibility enhancer. Morphologi-
cal investigation showed that the engineered particles have suit-
able aerodynamic particle size and relatively low physical
contact due to the corrugations on their surface, leading to
decreased density and hence high dispersibility. Different ratios
of polymer and levoﬂoxacin were studied to explore the effect of
increasing polymer concentration on aerosolization. These spray-
dried microparticles would be predicted to deposit predominately
in the deep lung following inhalation where infections predomi-
nate, with minimal oropharyngeal deposition, thereby maximizing
the dose delivered to the region of infection, increasing the efﬁ-
ciency of formulation and potentially reducing the occurrence of
toxicity in the oropharyngeal region or following swallowing. The
dispersibility of spray-dried formulations containing octanoyl
chitosan was comparable with those containing L-leucine, indicat-
ing its effectiveness as a dispersibility enhancer and suggesting its
inclusion may be attractive for pulmonary delivery of other drugs.
This natural polymer when hydrophobically modiﬁed would be
attractive for its dispersibility enhancement property as compared
to the model hydrophobic amino acid L-leucine due to its antibac-
terial and mucoadhesive properties. Mucoadhesion would increase
the residence time of the formulations in the lungs consequently
enhancing the efﬁciency of antibiotic for the treatment of
infections. Biodegradability of this natural polymer and the non-
cytotoxicity determined by MTT assay suggests the likely safety
of use of this polymer as dispersibility enhancer in formulations
for aerosolization.
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